Diabetes market set to reach $490B by 2030; NICE wants more RoActemra info;

@FiercePharma: Vioxx lawyers are still playing tug-of-war on legal fees. Why? Because it works. Item | Follow @FiercePharma

> Diabetes remains pharma's fastest-growing market, with projected 2030 sales of $490 billion, much of it in emerging markets. News

> A 25% increase in Russian sales, along with gains in several European countries, helped offset declines in Stada's home market of Germany, pushing first-half revenues to a record £830 million ($1.17 billion). Report

> The U.K.'s cost-effectiveness watchdog wants more information from Roche about RoActemra's utility in systemic juvenile arthritis. Article

> Medco Health Solutions executives will go live to take up their $27.5 billion sale to Express Scripts. Story

> Plaintiff lawyers in Vioxx litigation won an additional $3 million in fees by objecting to their original awards. Report

> Watson Laboratories got the tentative FDA nod for its version of the AstraZeneca statin drug Crestor in four strengths. Release

Biotech News

@FierceBiotech: Detector lets researchers see biomarkers with their naked eyes. News | Follow @FierceBiotech

@JohnCFierce: Some highlights of the PwC VC report. Biotech deals and dollars are down year over year. $ on early rounds grow. Report | Follow @JohnCFierce

@MaureenFierce: Paladin makes hostile bid for Afexa. Story | Follow @MaureenFierce

> Flow of biotech venture dollars and deals shrivels in Q2. More

> FDA green lights combo HIV drug from J&J, Gilead. News

> Designer T cells spur a cure in breakthrough leukemia study. Report

Manufacturing News

> Vintage pharmacist bottles revered in NJ. More

> Cannines ID Pfizer fakes, discern brands. Details

> Greeley at CIS: alignments that speed time into market, aid compliance. News

> GSK leads pharma charge to middle east. Story

> Pfizer piggybacks PAT to real-time release. Article

Vaccine News

> Celldex stock hit had, but cancer vaccine shows promise. Story

> TB remedy could further the cancer fight. More

> Aeras kicks off TB trial in HIV patients. Report

> FBI raids San Diego's NexBio. Details

> University gets $4.8M grant for new rabies treatment. Story

And Finally... After 20 years of work, researchers have managed to use gene therapy to destroy cancerous tumors. Report

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.